GLP-1 Drugs Suppressed Reward Feeding Through a Central Amygdala Circuit
TL;DR: A 2026 mouse study in Nature found that small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs), obesity and diabetes drugs built around a glucose-linked hormone pathway, suppressed palatable-food intake through central amygdala neurons that lowered nucleus accumbens dopamine. Key Findings Humanized mouse model: Researchers engineered mice so small-molecule GLP-1 receptor agonists could be studied despite …
